Materialise NV reported third-quarter earnings of $0.03 per share on revenue of $76.84 million. Earnings fell 25.0% year over year, and dollar-denominated revenue fell 1.2%. No consensus estimate was available, so this quarter is best judged against the company's own trajectory, and that comparison is less flattering than the prior quarter's. In euros, the reporting currency, revenue rose 2.1% to €67.7 million, or 4.9% excluding last year's revenue from the divested RapidFit and Eyewear businesses. That was a clear slowdown from roughly 8% growth in the second quarter. Management reaffirmed full-year guidance and cash generation set new highs. Still, the central tension is that earnings power stepped backward just as the stock was trading near its best levels of the year.

The quality of the quarter deserves scrutiny. Gross margin improved 90 basis points to 57.7%, so the pressure came from below the gross line. Operating expenses rose 7.8%, led by an 11.9% increase in R&D, and operating profit nearly halved to €1.3 million from €2.5 million. Adjusted EBIT fell to €2.5 million from €2.9 million a year ago and €3.9 million in the second quarter. The adjusted EBIT margin compressed to 3.7% from 5.5% sequentially, back to first-quarter levels. Even adjusted earnings absorbed some one-time costs. The add-backs also grew: share-based compensation rose to €360,000 from €74,000, and restructuring charges and a small Eyewear inventory impairment were excluded as well. Net profit of €1.4 million was cushioned by a positive financial result and a much lower tax charge. Without those, the bottom-line decline would have been steeper. Net profit was also well below the €3.3 million earned in the second quarter.

Segment trends explain the slowdown, and they are not uniformly bad.

• **Medical:** Revenue grew 9.7%, with both devices and medical software up about 10%. For medical software, that marks a turnaround from declines in the first two quarters. The segment's adjusted EBITDA margin, however, fell to 27.4% from 30.6% a year ago and about 31% in the second quarter, as management deliberately stepped up R&D.
• **Software:** This is the clearest problem area. Revenue fell 4%, extending a worsening pattern from -1% in the first quarter and -3% in the second. Management cited cautious customer spending and longer CoEM sales cycles, and segment margin slipped to 14.8% from 17.5%.
• **Manufacturing:** Reported revenue fell 6% but rose 1.5% excluding divestitures, a sharp cooling from 7% growth in the second quarter, as prototyping remained soft. Beneath that, series production in core aerospace, semiconductor and defense markets grew more than 30% and is now roughly balanced with prototyping work. The segment's EBITDA loss also narrowed to €0.3 million from €0.8 million.

The forward-looking evidence is credible but still early-stage. Catalysts include:

• an agreement with Superhuman Center in Ukraine covering hundreds of cranio-maxillofacial patients plus surgeon training;
• tripled volumes for FITS Dynaprint following its U.S. launch;
• new CoEM new-product-introduction deals with aerospace customers;
• AI-powered cardiac and liver surgical planning workflows;
• investment in larger metal additive manufacturing capacity for defense.

The balance sheet gives management room to pursue these. Net cash climbed to €82.5 million from €74.2 million in the second quarter, year-to-date free cash flow of €22.8 million is more than double last year's, and buybacks reached €7.5 million. Gross debt did rise to €71 million after the final €15 million credit-facility drawdown.

Guidance is where the setup gets more demanding. The reaffirmed ranges are €273 million to €283 million in revenue and €12 million to €14 million in adjusted EBIT. Against year-to-date figures of €204.0 million in revenue and €8.8 million in adjusted EBIT, even the low end requires a fourth quarter of roughly €69 million in revenue and at least €3.2 million in adjusted EBIT. Both would be improvements on the third quarter. Year-to-date adjusted EBIT is up 33%, so the annual story remains intact. Hitting the targets, though, depends on a sequential rebound that this quarter did not preview.

The market had been pricing in a better narrative. Shares closed at $8.62 ahead of the report, up 19.7% from the $7.20 opening after the August release. That left them about 35.5% above the 200-day moving average and just 2.3% below the $8.82 inter-earnings high set on September 29, which was also a 52-week high. Price, momentum and AVWAP trend readings were positive heading into the print. Investor sentiment moved the other way, slipping from roughly neutral at -0.02 to -0.19. That is a meaningful but not dramatic shift toward skepticism while the stock was rising.

The bottom line is that Materialise delivered a reaffirm quarter with a strong cash story and improving Medical and series-manufacturing trends. Lower adjusted EBIT, decelerating growth and a deteriorating Software business undercut the momentum built in the second quarter. Bears have legitimate ammunition in the margin reset and the back-end-loaded guidance. With shares entering the report near their highs, the fourth quarter now has to prove that higher R&D spending is an investment rather than a drag.